Palatin Technologies Initiates Phase 2 Hypertension Clinical Study Wi... ( CRANBURY N.J. May 20 /- Palatin T...)

Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994

Date:5/20/2008

CRANBURY, N.J., May 20 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced today that dosing has been initiated in a Phase 2a clinical study of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension.

The study is placebo-controlled and double-blinded, and will include up to five cohorts receiving escalating doses. As many as 35 subjects will be included, with six active subjects and one placebo subject per dose cohort. Subjects passing screening are admitted to a research clinic, placed on a controlled diet and have baseline blood pressures and laboratory values monitored for 24 hours. The next morning, subjects receive a single dose of PL-3994 or placebo with blood pressures and laboratory values monitored for 24 hours. Every other week, another cohort of subjects will receive a higher dose of PL-3994 until a pre-specified blood pressure decrease is observed.

"We are excited with our PL-3994 program's rapid progress. Data from these hypertensive patients will provide key indications of the compound's therapeutic potential," stated Dr. Trevor Hallam, Palatin's Executive Vice President for Research and Development. "We look forward to the completion of this study as well as the reporting of results next quarter."

Based on the results of this study and the previously completed Phase 1 trial in healthy, non-hypertensive volunteers, a Phase 2 trial in patients with episodes of hypertensive urgency is planned for later this calendar year. Palatin is also developing PL-3994 for the treatment of acute decompensated congestive heart failure and plans to initiate a separate Phase 2 study in these patients later this calendar year.

About Acute
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
5. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
6. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
7. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
8. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
9. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Senesco Technologies Initiates Preclinical Studies for Cancer Target

Post Your Comments:

Palatin Technologies Initiates Phase 2 Hypertension Clinical Study Wi...( CRANBURY N.J. May 20 /- Palatin T...),Health